Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Licensing deals
Biotech
Sanofi mulling ‘moonshot’ M&A targets to survive Dupixent cliff
Sanofi is considering “moonshot” treatments among the acquisition targets to urgently replenish its pipeline, CFO François-Xavier Roger told Fierce.
James Waldron
Oct 30, 2026 3:27am
BioMarin inks up to $475M deal to challenge Fabry ERT incumbents
Oct 29, 2026 10:13am
Astellas makes $1.3B bet on Audax’s preclinical IL-12 program
Oct 28, 2026 5:37am
Roche pays Zymeworks $55M for challenger to Amgen’s Imdelltra
Oct 23, 2026 7:28am
Treasury COINS rules add biotech, spares China licensing deals
Oct 22, 2026 11:36pm
Menarini gets Georgiamune preclinical cancer drug in $1B deal
Oct 22, 2026 10:50am
